Congruence Therapeutics to Present at Multiple Upcoming Investor Conferences
- 23rd Annual Needham Virtual Healthcare Conference, being held in a virtual format
April 8-11, 2024 .Clarissa Desjardins , Ph.D., CEO of Congruence, will present a company overview onTuesday, April 9 th at9:30 am ET . Company management will also participate in one-on-one meetings with investors at this conference. - 2024 Bloom Burton & Co. Healthcare Investor Conference, being held
April 16-17, 2024 , inToronto, Ontario .Dr. Desjardins will present a company overview onTuesday, April 16 at1:30 pm ET . Company management will also participate in one-on-one meetings with investors at this conference.
About Congruence Therapeutics
Congruence is a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Our proprietary scalable platform, Revenir™, captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter.
For more information, please visit www.congruencetx.com.
Company Contact
Charles Grubsztajn
Chief Operating Officer
[email protected]
Media Contact
[email protected]
858-366-3243
View original content to download multimedia:https://www.prnewswire.com/news-releases/congruence-therapeutics-to-present-at-multiple-upcoming-investor-conferences-302101538.html
SOURCE Congruence Therapeutics
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bugatti Showcases Steve Dimopoulos' One-of-One Chiron at Pebble Beach Automotive Week
- Granite Asia Ranked No. 1 Leading Financial Firm in Singapore for 2026, Metaclade Research Finds
- CPKC and IBEW agree to binding arbitration ending strike
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share